Hypoglycemia and resistance to ketoacidosis in a subject without functional insulin receptors.

Humans with congenital absence of the islets of Langerhans and mice rendered null for the insulin receptor rapidly develop severe hyperglycemia and ketoacidosis and, if untreated, die in the early neonatal period. In contrast, children with homozygous or compound heterozygous mutations of the insulin receptor gene, although hyperglycemic postprandially, survive for many months without developing ketoacidosis. Paradoxically, they often develop hypoglycemia. The rarity of the condition and the difficulties of undertaking metabolic studies in ill infants have limited the physiological information that might explain the clinical features. We studied a boy with Donohue's syndrome who represents a further example of the null phenotype, with two different and novel nonsense mutations in the alpha-subunit of the receptor. He survived for 8 months without developing ketoacidosis, and fasting hypoglycemia was a frequent problem. Despite the complete absence of insulin receptors, evidence for persistent insulin-like effects on fat and liver was seen; fasting plasma beta-hydroxybutyrate and nonesterified fatty acid levels were low, fell further during the early postprandial period, and failed to rise in response to hypoglycemia. The inverse relationships between plasma insulin and insulin-like growth factor-binding protein-1 levels were maintained, suggesting persistent hepatic effects of insulin. GH levels measured over a 6.5-h period were low throughout. Thus, the differences between congenital insulin deficiency vs. insulin receptor deficiency in humans may be explained by persistent insulinomimetic activity of the grossly elevated plasma insulin presumably being mediated through the type 1 insulin-like growth factor receptor. As GH plays a critical role in the regulation of ketogenesis during insulinopenia in humans, but not in rodents, this may contribute to the distinct phenotype of human vs. mouse insulin receptor knockouts.

[1]  D. Dunger,et al.  Insulin, insulin-like growth factor I (IGF-I), IGF-binding protein-1, growth hormone, and feeding in the newborn. , 1998, The Journal of clinical endocrinology and metabolism.

[2]  D. Dunger,et al.  The Use of an Automated Microsampling System for the Characterization of Growth Hormone Pulsatility in Newborn Babies , 1997, Pediatric Research.

[3]  S. Amselem,et al.  Severe resistance to insulin and insulin-like growth factor-I in cells from a patient with leprechaunism as a result of two mutations in the tyrosine kinase domain of the insulin receptor. , 1996, Metabolism: clinical and experimental.

[4]  M. Savage,et al.  Growth hormone insensitivity syndrome (Laron syndrome): main characteristics and effects of IGF1 treatment. , 1996, Diabetes & metabolism.

[5]  K. Tsuchihashi,et al.  Acute and chronic regulation of serum sex hormone-binding globulin levels by plasma insulin concentrations in male noninsulin-dependent diabetes mellitus patients. , 1996, The Journal of clinical endocrinology and metabolism.

[6]  P. Douglas,et al.  Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. , 1996, Circulation.

[7]  K. Albertsson-Wikland,et al.  Spontaneous 24-hour growth hormone profiles in prepubertal small for gestational age children. , 1995, The Journal of clinical endocrinology and metabolism.

[8]  D. Accili Molecular defects of the insulin receptor gene. , 1995, Diabetes/metabolism reviews.

[9]  P F Williams,et al.  Mapping of an NH-terminal Ligand Binding Site of the Insulin Receptor by Alanine Scanning Mutagenesis (*) , 1995, The Journal of Biological Chemistry.

[10]  R. Rizza,et al.  Islet amyloidosis in a patient with chronic massive insulin resistance due to antiinsulin receptor antibodies. , 1994, The Journal of clinical endocrinology and metabolism.

[11]  W. Möller,et al.  A mutation in the insulin receptor that impairs proreceptor processing but not insulin binding. , 1994, The Journal of biological chemistry.

[12]  S. O’Rahilly,et al.  Molecular Scanning of the Insulin Receptor Gene in Syndromes of Insulin Resistance , 1994, Diabetes.

[13]  P. Pilch,et al.  The insulin receptor: structure, function, and signaling. , 1994, The American journal of physiology.

[14]  M. B. Fritz Management of the menopause , 1993, The Lancet.

[15]  Simeon I. Taylor,et al.  Leprechaunism and homozygous nonsense mutation In the insulin receptor gene , 1993, The Lancet.

[16]  S. O’Rahilly,et al.  Homozygous nonsense mutation in the insulin receptor gene in infant with leprechaunism , 1993, The Lancet.

[17]  David Valle,et al.  The skipping of constitutive exons in vivo induced by nonsense mutations , 1993, Science.

[18]  K. Siddle,et al.  A monoclonal anti-peptide antibody reacting with the insulin receptor beta-subunit. Characterization of the antibody and its epitope and use in immunoaffinity purification of intact receptors. , 1992, The Biochemical journal.

[19]  Simeon I. Taylor,et al.  Lilly Lecture: Molecular Mechanisms of Insulin Resistance: Lessons From Patients With Mutations in the Insulin-Receptor Gene , 1992, Diabetes.

[20]  A. Ullrich,et al.  A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. , 1992, The Journal of biological chemistry.

[21]  K. Alberti,et al.  Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men. , 1992, The Journal of clinical endocrinology and metabolism.

[22]  R. Roth,et al.  A region of the insulin receptor important for ligand binding (residues 450-601) is recognized by patients' autoimmune antibodies and inhibitory monoclonal antibodies. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[23]  W. Lee,et al.  Measurement of insulin-like growth factor-II in physiological fluids and tissues. I. An improved extraction procedure and radioimmunoassay for human and rat fluids. , 1991, Endocrinology.

[24]  Simeon I. Taylor,et al.  Mutagenesis of lysine 460 in the human insulin receptor. Effects upon receptor recycling and cooperative interactions among binding sites. , 1990, The Journal of biological chemistry.

[25]  K. Frayn,et al.  Micro-Method for Measurement of Sub-Nanomole Amounts of Triacylglycerol , 1990, Annals of clinical biochemistry.

[26]  K. Siddle,et al.  Identification of epitopes on the human insulin receptor reacting with rabbit polyclonal antisera and mouse monoclonal antibodies. , 1990, The Journal of biological chemistry.

[27]  D. Dunger,et al.  THE GROWTH HORMONE INDEPENDENT INSULIN‐LIKE GROWTH FACTOR‐I BINDING PROTEIN BP‐28 IS ASSOCIATED WITH SERUM INSULIN‐LIKE GROWTH FACTOR‐I INHIBITORY BIOACTIVITY IN ADOLESCENT INSULIN‐DEPENDENT DIABETICS , 1990, Clinical endocrinology.

[28]  D. Owens,et al.  Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. , 1989, The Biochemical journal.

[29]  Robert E. Jones,et al.  Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. , 1988, The Journal of clinical endocrinology and metabolism.

[30]  W. Rutter,et al.  Expression and characterization of a functional human insulin-like growth factor I receptor. , 1988, The Journal of biological chemistry.

[31]  K. Frayn,et al.  Micro-method for preparing perchloric extracts of blood. , 1988, Clinical chemistry.

[32]  V. Maes,et al.  HPLC method for assay of bamifylline in plasma from neonates. , 1988, Clinical chemistry.

[33]  P. Arner,et al.  Studies of acute effects of insulin-like growth factors I and II in human fat cells. , 1987, The Journal of clinical endocrinology and metabolism.

[34]  S. Chernausek,et al.  Characteristics of hepatic receptors for somatomedin-C/insulin-like growth factor I and insulin in the developing human. , 1987, The Journal of clinical endocrinology and metabolism.

[35]  K. Siddle,et al.  Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor. , 1986, The Biochemical journal.

[36]  R. Roth,et al.  Monoclonal antibodies to the human insulin receptor block insulin binding and inhibit insulin action. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[37]  E. Van Obberghen,et al.  Demonstration of two subtypes of insulin-like growth factor receptors by affinity cross-linking. , 1981, The Journal of biological chemistry.

[38]  J. Olefsky,et al.  Glucose kinetics in leprechaunism: accelerated fasting due to insulin resistance. , 1980, The Journal of clinical endocrinology and metabolism.

[39]  A. Plet,et al.  Leprechaunism: studies of the relationship among hyperinsulinism, insulin resistance, and growth retardation. , 1979, The Journal of clinical endocrinology and metabolism.

[40]  K. Laurence,et al.  Congenital absence of islets of Langerhans. , 1977, Archives of disease in childhood.

[41]  L. Phillips,et al.  The effects of insulin and growth hormone on the release of somatomedin by the isolated rat liver. , 1976, Endocrinology.

[42]  A. Abrahamov,et al.  Leprechaunism (Donohue syndrome). , 1973, American journal of diseases of children.

[43]  D. Cocchi,et al.  Ineffectiveness of hypoglycemia, cold exposure and fasting in stimulating GH secretion in the mouse. , 1971, Endocrinology.

[44]  M. Salmon,et al.  Dystrophic Changes Associated with Leprechaunism in a Male Infant , 1963, Archives of disease in childhood.

[45]  I. Uchida,et al.  Leprechaunism: a euphemism for a rare familial disorder. , 1954, The Journal of pediatrics.

[46]  Mark D. Johnson,et al.  Early neonatal death in mice homozygous for a null allele of the insulin receptor gene , 1996, Nature Genetics.

[47]  D. Accili,et al.  Homozygosity for a null allele of the insulin receptor gene in a patient with leprechaunism , 1995, Human mutation.

[48]  B. Ursø,et al.  The Insulin-Like Growth Factor-I Receptor , 1994, Hormone Research.

[49]  Simeon I. Taylor,et al.  Homozygous deletion of the human insulin receptor gene results in leprechaunism , 1993, Nature Genetics.

[50]  T. Chard,et al.  Purification and assay of insulin-like growth factor-binding protein-1: measurement of circulating levels throughout pregnancy. , 1991, The Journal of endocrinology.

[51]  R. Koistinen,et al.  Dose-response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin. , 1989, The Journal of clinical endocrinology and metabolism.